Results 41 to 50 of about 2,203,437 (159)

Transcatheter Tricuspid Valve-in-Valve Replacement Using a J-Valve System for a Failed Tricuspid Bioprosthesis

, 2022
BACKGROUND: Redo operation for failed tricuspid bioprosthetic valves is associated with high morbidity and mortality. Transcatheter tricuspid valve-in-valve implantation has become an acceptable option for high-risk patients with a failed tricuspid ...
Miao, Lifu, Tang, Xiujie, Zhang, Mingkui, Xue, Hui, Xiujie Tang, Lifu Miao, Hui Xue, Yanbin Shao, Shao, Yanbin, Mingkui Zhang   +9 more
core   +1 more source

Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures?

Life, 2023
Tricuspid regurgitation (TR) is a common valvular pathology, estimated to affect 1.6 million people in the United States alone. Even though guidelines recommend either medical therapy or surgical treatment for TR, the misconception of TR as a benign ...
Kyriakos Dimitriadis, Nikolaos Pyrpyris, Konstantinos Aznaouridis, Panagiotis Iliakis, Aggeliki Valatsou, Panagiotis Tsioufis, Eirini Beneki, Emmanouil Mantzouranis, Konstantina Aggeli, Eleftherios Tsiamis, Konstantinos Tsioufis   +10 more
doaj   +1 more source

Transcatheter Tricuspid Valve Clinical Trials: Incomplete Data and FDA-Approved Devices

Structural Heart
Each reviewed trial of transcatheter tricuspid valve intervention demonstrated clinically meaningful improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ)-defined quality of life and favorable right ventricular remodeling.
Deborah Furman, MD, Brian Whisenant, MD
doaj   +1 more source

Tratamiento endovascular de la válvula tricúspide: estado actual

Cirugía Cardiovascular, 2021
Resumen: De acuerdo con los últimos estudios, la tasa de intervención quirúrgica de la válvula tricúspide es muy baja, pese al gran número de pacientes con insuficiencia tricuspídea severa con indicación de cirugía, según las guías de práctica clínica ...
Gertrudis Parody-Cuerda, Emiliano Rodríguez-Caulo, José Miguel Barquero-Aroca   +2 more
doaj   +1 more source

Transcatheter Tricuspid Valve Replacement for Residual Tricuspid Regurgitation After TEER

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Residual or recurrent tricuspid regurgitation (TR) after prior transcatheter tricuspid edge‐to‐edge (T‐TEER) repair occurs in about 12% of patients within 1 year. Since surgical tricuspid valve repair or replacement is of high risk, treatment options remain scarce.
Fabian Voß, Philipp Mourikis, Fabian Nienhaus, Jafer Haschemi, Alexander Hoss, Tobias Zeus, Hanna Kowalski, Maximilian Spieker, Christian Jung, Patrick Horn, Hug Aubin, Artur Lichtenberg, Richard Truse, Malte Kelm, Amin Polzin   +14 more
wiley   +1 more source

Transcatheter therapies for tricuspid valve regurgitation

, 2020
: Tricuspid regurgitation, either isolated or associated with left-valve disease, has a strong impact on outcome. Surgical treatment of tricuspid regurgitation has increased in recent years, but in-hospital mortality remains high probably due to the risk
Fiorina C., Metra M., Adamo M., Zaccone G., Di Pasquale M., Curello S.   +5 more
core   +1 more source

Successful Percutaneous Retrieval of an Embolized MitraClip From the Right Subclavian Artery

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Single leaflet device attachment (SLDA) after mitral transcatheter valve edge‐to‐edge repair (M‐TEER) has been reported in up to 5% of patients. However, complete embolization of the M‐TEER device is exceedingly rare. Device retrievals in all previously reported cases were completed by vascular surgery cut down at the end. In this case, we are
Seyed Hossein Aalaei‐Andabili, Diljon S. Chahal, Shahab Tour Savadkohi   +2 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Transcatheter versus surgical aortic-valve replacement in high-risk patients. [PDF]

, 2011
BACKGROUND: The use of transcatheter aortic-valve replacement has been shown to reduce mortality among high-risk patients with aortic stenosis who are not candidates for surgical replacement.
Makkar, Raj R, Samir Kapadia, Dewey, Todd, Pichard, Augusto D, Mack, Michael J, Vinod H. Thourani, Duolao Wang, Smith, Craig R, Webb, John G, Babaliaros, Vasilis, Moses, Jeffrey W, D. Craig Miller, Jeffrey W. Moses, Wang, Duolao, Craig R. Smith, Mathew Williams, Todd Dewey, Miller, D Craig, Michael J. Mack, John G. Webb, William N. Anderson, Tuzcu, E Murat, Thourani, Vinod H, Raj R. Makkar, Gregory P. Fontana, Svensson, Lars G, Kapadia, Samir, E. Murat Tuzcu, Paul Corso, Martin B. Leon, Williams, Mathew, Stuart J. Pocock, Bavaria, Joseph E, MD, Howard C. Herrmann, Augusto D. Pichard, Lars G. Svensson, Pocock, Stuart J, Jodi J. Akin, Joseph E. Bavaria, Fontana, Gregory P, Akin, Jodi J, Corso, Paul, Bavaria, Joseph E, Leon, Martin B, Herrmann, Howard C, PARTNER Trial Investigators, Anderson, William N, Vasilis Babaliaros   +47 more
core   +1 more source